Role of Everolimus on Cardiac Functions in Kidney Transplant Recipients.
BACKGROUND
Kidney transplantation is known to increase the survival of dialysis patients by ameloriating cardiac status, including both systolic and diastolic functions. We aimed to evaluate the role of immunosuppressive drug regimens on cardiac functions of kidney transplant recipients (KTRs).


METHODS
We prospectively evaluated 120 KTRs immediately before and 1 year after the kidney transplantation, using tissue Doppler echocardiography. A triple immunosuppressive therapy including tacrolimus, mycophenoloic acid (MPA), and prednisolone was started for all patients. After 3 to 6 months, the tacrolimus dose was lowered to achieve target serum levels of 5 to 8 ng/mL in both groups. MPA was switched to everolimus, with target levels of 4 to 6 ng/mL, in group 1 (n = 58), whereas group 2 (n = 62) continued with MPA.


RESULTS
No differences in age, sex, or dialysis duration existed between the groups. The prevalence of diabetic or hypertensive nephropathy as the etiology of chronic kidney disease was similar. Blood pressure was strictly controlled. The number of acute rejection episodes was not different in both groups, and no graft loss was observed in either group. Improvement in cardiac parameters including ejection fraction, left ventricular diastolic diameter, posterior wall thickness, and left ventricular hypertrophy was significantly better before and 1 year after transplantation. Interestingly, when compared with group 2, ameloriation of all of the parameters mentioned above was even better in group 1 patients (P = .02, P = .03, P = .04, and P = .04, respectively). Multivariate analysis of the significant variables determined by univariate analysis identified albumin (relative risk [RR] = 1.05, P = .02) and everolimus (RR = 1.07, P = .01) as two independent factors of improving cardiovascular function.


CONCLUSIONS
Better ameloriation of cardiovascular functions with everolimus may favor the choice of this drug in KTRs.
Transplant Center, Acibadem International Hospital, Acibadem University, Istanbul, Turkey. Electronic address: ulkem.cakir@internationalhospital.com.tr.
U
U
Cakir
Transplant Center, Acibadem International Hospital, Acibadem University, Istanbul, Turkey.
G
G
Alis
Transplant Center, Acibadem International Hospital, Acibadem University, Istanbul, Turkey.
T
T
Erturk
Transplant Center, Acibadem International Hospital, Acibadem University, Istanbul, Turkey.
A H
AH
Karayagiz
Cardiology Department, Acibadem Healthcare Group, Istanbul, Turkey.
U
U
Karabulut
Transplant Center, Acibadem International Hospital, Acibadem University, Istanbul, Turkey.
I
I
Berber
D000328:Adult; D003920:Diabetes Mellitus / Q000209:etiology; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000209:etiology; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D000068338:Everolimus; D016559:Tacrolimus